| Autor: |
Hayes SM; University of Minnesota Medical Center - Fairview, 420 Delaware Street SE, MMC 611, Minneapolis, MN 55455, USA., Wasko JA; University of Minnesota Medical Center - Fairview, 420 Delaware Street SE, MMC 611, Minneapolis, MN 55455, USA., Warlick ED; Department of Hematology, Oncology, and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA. |
| Abstrakt: |
We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney injury. Given previous prolonged remission achieved with clofarabine and cytarabine therapy years prior, rechallenge was undertaken upon discovery of AML relapse. We designed a desensitization protocol performed with the first dose of clofarabine, leading to successful administration of the entire clofarabine/cytarabine treatment course. From this case we show promise for clofarabine rechallenge after prior hypersensitivity reactions in patients with few treatment options for relapsed AML. |
